Our analysis demonstrates that prognostic pathways in HER2+ and ER−/HER2− breast cancer are far more similar to prognostic pathways in angiogenic and non-angiogenic ovarian cancer than to prognostic pathways in ER+ breast cancer. This evidence concerns the gene ERBB2 and ovarian carcinoma.